export const teamMembers = [
  {
    name: "Marc Shirman",
    role: "Board Director",
    image: "/marc.jpg", // Renamed to local path
    description: `Marc Shirman joined the board in 2023 to manage
the bridge capital investment in Blueberry.
Following the acquisition by Sanoderm, Marc is
responsible for commercialising the assets of the
business. He is formerly the Co-Head of UK Private
Capital at Muzinich & Co and previously Head of
Financial Sponsors at NatWest Markets.`,
  },
  {
    name: "Rita Dobmeyer",
    role: "Board Member",
    image: "/rita.jpg", // Renamed to local path
    description:
      "Rita Dobmeyer is the CEO of the European CRO Galenus G&H AG. Prior to this she was Director of European Consulting and Client Relations for Parexel GmbH, and Director of Phase IV Clinical Services and Post-Marketing Surveillance at IMS Health. Rita is the founder of eight companies and has networks with investors and key opinion leaders around the world. She is a graduate of the University of Kaiserslautern, with a PhD in infection from the German Cancer Research Centre, Heidelberg.",
  },
  {
    name: "Arnold Wong",
    role: "Board Member",
    image: "/arnold.jpg", // Renamed to local path
    description: `Cofounder of multi-national CRO Inclin, has hands-
on experience in pre-clinical pharmacology drug
development and extensive experience in clinical
project management. He brings over thirty years of
experience to an organization recognized for its
commitment to quality, clinical experience and high
employee retention. He began his career as a
research scientist at Cardima, Inc., COR
Therapeutics, and Syntex Research.`,
  },
  {
    name: "A Ray Chaudhuri",
    role: "Executive Chair",
    image: "/ray.jpg", // Renamed to local path
    description:
      "Bob Clay is a pharmacist with more than 30 years of experience in drug development, leading the global regulatory approval of many products across a range of therapy areas, including more than 15 new active substances. Previously, he was VP of Global Regulatory Affairs at AstraZeneca with responsibility for oncology, infection and personalised healthcare. Bob is a Fellow and Board Member at TOPRA (President in 2017) and a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture. Bob has held significant leadership roles in regulatory affairs in regional and global functions at Pfizer, AstraZeneca and Kinapse.",
  },
  {
    name: "Liam Good",
    role: "CSO",
    image: "/liam.jpg", // Renamed to local path
    description: `Liam is the founder of Tecrea, a pioneering
R&D company in the field of molecular science. By creating a patented
nanotechnology platform, Tecrea provides a unique range of cell and tissue delivery
tools that are fully translatable from the lab to the clinic.`,
  },
  {
    name: "Juergen Dobmeyer",
    role: "CMO",
    image: "/juergen.jpg", // Renamed to local path
    description: `Seasoned clinical development executive and research physician, expertise in infectious disease, oncology, and rare diseases. Successfully led global Phase 1 to NDA programs, and built lasting industry relationships for
Celegene, BMS, Boehringer Ingelheim, Roche, Novartis, JnJ, and multiple start-up companies. He has held management roles at the Institute for Medical Statics, Frankfurt, and at IMS Health (now IQVIA), covering drug safety services, portfolio optimization, forecasting, and launch and brand management.`,
  },
  {
    name: "Jonathan Hodari",
    role: "COO",
    image: "/jonathan.jpg", // Renamed to local path
    description: `J runs the Investment Portfolio for Pilot
Group, a principle shareholder in
Sanoderm. He is the operational partner on
a number of early-stage companies and a
Consultant Active Partners`,
  },
];
